Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

Catalent Inc. (CTLT) announced Loss for first quarter that decreased from last year The company's bottom line totaled -$129 million, ...

On Monday, Catalent Inc (CTLT) stock saw a decline, ending the day at $58.69 which represents a decrease of $-0.04 or -0.07% from the prior close of $58.73. The stock opened at $58.92 and touched a ...

The UK government said on Tuesday it has confirmed a strain of the H5N5 bird flu virus in commercial poultry at a premises ...

Viatris Inc. today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The ...

The oral dosing cup market is poised for significant growth over the next decade, with projections indicating an increase ...

Numerous global surveys have found that wellness matters more to people each year post pandemic. With today's release of the Global ...